Teriparatide 20mcg Injection — Parathyroid Hormone Analogue for Osteoporosis Treatment
Forteo® (Teriparatide) — Parathyroid Hormone Analogue for Osteoporosis
The Only Anabolic Bone-Building Treatment for Severe Osteoporosis
Forteo® (Teriparatide) is a recombinant human parathyroid hormone analogue used to treat osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis at high risk of fracture. Unlike antiresorptive treatments that slow bone loss, Forteo works by actively stimulating new bone formation — making it the first true anabolic bone-building treatment approved for osteoporosis.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Forteo (Teriparatide) to hospitals, orthopaedic centres, endocrinology clinics, and pharmacies across India. Teriparatide is also available as Terifrac — another brand supplied by A.K. Pharma. Forteo is manufactured by Eli Lilly and Company, a global leader in bone health medicines.
What is Forteo (Teriparatide)?
Forteo contains Teriparatide, a synthetic form of the 34 amino acid N-terminal fragment of human parathyroid hormone (PTH 1-34). When administered as a once-daily subcutaneous injection, intermittent Teriparatide stimulates osteoblast activity — increasing bone formation more than bone resorption — resulting in a net increase in bone mineral density (BMD) and bone strength.
This anabolic mechanism is fundamentally different from antiresorptive agents such as bisphosphonates or Denosumab, which work by slowing bone breakdown. Forteo actually builds new bone, making it particularly valuable in patients with severe osteoporosis or those who have failed antiresorptive therapy.
Full prescribing information is available at the FDA label for Teriparatide.
Clinical Studies and Evidence
Fracture Prevention Trial (FPT) — Pivotal Teriparatide Trial Published in the New England Journal of Medicine (2001), the FPT demonstrated that Teriparatide significantly reduced vertebral fractures by 65% and non-vertebral fragility fractures by 53% compared to placebo in postmenopausal women with osteoporosis over 21 months of treatment.
Glucocorticoid-Induced Osteoporosis Trial Published in the New England Journal of Medicine (2007), a head-to-head trial demonstrated Teriparatide was significantly more effective than Alendronate in increasing lumbar spine BMD and reducing vertebral fractures in patients with glucocorticoid-induced osteoporosis.
VERO Trial (Teriparatide vs Risedronate) Published in The Lancet (2017), the VERO trial — the first head-to-head fracture outcomes trial of an anabolic vs antiresorptive agent — demonstrated that Teriparatide reduced new vertebral fractures by 56% compared to Risedronate over 24 months in postmenopausal women with severe osteoporosis.
DATA Study (Teriparatide + Denosumab Combination) The DATA study showed that combination therapy with Teriparatide and Denosumab produced greater increases in BMD than either agent alone, suggesting potential for combination approaches in the most severe cases.
Available Strengths
Forteo is available as:
The recommended dose is 20mcg subcutaneously once daily. Maximum treatment duration is 24 months (2 years) due to the theoretical risk of osteosarcoma observed in rat studies. Forteo should not be re-administered after the 24-month treatment course.
Indications — What Forteo is Used For
For detailed indication information refer to NCI Teriparatide Drug Information or MedlinePlus Teriparatide.
Key Benefits of Forteo
Anabolic Bone Building — Not Just Antiresorptive Forteo is the only treatment that actively builds new bone rather than simply slowing bone loss. This distinction is critical in patients with severe osteoporosis where existing bone mass is severely compromised.
Proven Fracture Reduction Forteo reduces vertebral fractures by up to 65% and non-vertebral fractures by 53% — among the strongest fracture reduction data of any osteoporosis treatment.
Superior to Bisphosphonates in Severe Cases Head-to-head trials including the VERO trial demonstrate Forteo’s superiority over antiresorptive agents in reducing fractures in patients with severe osteoporosis.
Effective in Glucocorticoid-Induced Osteoporosis Forteo is one of the few treatments demonstrated to be effective in glucocorticoid-induced osteoporosis — a particularly challenging form of the disease seen in patients on long-term steroid therapy.
Rapid Onset of Effect Significant increases in bone mineral density are seen within 3-6 months of starting treatment, with continued improvement over the full 24-month treatment course.
Followed by Antiresorptive Consolidation After completing Forteo treatment, patients are transitioned to antiresorptive therapy (e.g. Prolia/Denosumab) to consolidate and maintain the gains in bone density achieved.
How Forteo Works
Parathyroid hormone (PTH) regulates calcium and phosphate metabolism and plays a key role in bone remodelling. When PTH levels are continuously elevated (as in hyperparathyroidism), bone is broken down. However when PTH is administered intermittently — as with once-daily Forteo injection — the anabolic effects predominate:
For a detailed mechanism overview refer to the International Osteoporosis Foundation.
Forteo vs Prolia — Key Differences
| Feature | Forteo (Teriparatide) | Prolia (Denosumab) |
|---|---|---|
| Mechanism | Anabolic — builds new bone | Antiresorptive — slows bone loss |
| Administration | Daily injection | Every 6 months injection |
| Treatment Duration | Maximum 24 months | Ongoing |
| Best For | Severe osteoporosis, failed antiresorptive | Postmenopausal osteoporosis, ongoing prevention |
| Fracture Reduction | Vertebral 65%, non-vertebral 53% | Vertebral 68%, non-vertebral 20% |
| Available at A.K. Pharma | Request Quote | Request Quote |
Dosage and Administration
Full dosing guidelines available at Drugs.com Teriparatide Dosage.
Who Should Use Forteo
Forteo is prescribed for:
Forteo is prescribed by endocrinologists, orthopaedic surgeons, rheumatologists, and general physicians. A.K. Pharma supplies Forteo to hospitals, orthopaedic centres, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include nausea, headache, dizziness, leg cramps, and injection site reactions. Transient hypercalcaemia may occur and typically resolves within a few hours.
Serious side effects include:
Full side effect information available at FDA Teriparatide Safety Information.
Precautions and Contraindications
Forteo is contraindicated in:
Additional precautions:
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma maintains strict cold chain requirements during storage and supply of Forteo, ensuring full product integrity for every unit supplied.
Manufacturer Information
Forteo (Teriparatide) is manufactured by Eli Lilly and Company, a global pharmaceutical company with over 140 years of experience. Forteo received FDA approval in November 2002 as the first anabolic treatment for osteoporosis. A.K. Pharma supplies only genuine Forteo sourced from authorized distributors.
Related Bone Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Forteo used for? Forteo (Teriparatide) is used to treat severe osteoporosis in postmenopausal women, men with osteoporosis, and patients with glucocorticoid-induced osteoporosis at high risk of fracture. More information available at MedlinePlus.
Q. What is the generic name of Forteo? The generic name of Forteo is Teriparatide. It belongs to the parathyroid hormone analogue class of bone medicines. Teriparatide is also available as Terifrac.
Q. How is Forteo different from Prolia? Forteo builds new bone (anabolic) while Prolia slows bone loss (antiresorptive). Forteo is used for a maximum of 24 months in severe cases, after which patients are transitioned to Prolia or bisphosphonates to consolidate and maintain gains.
Q. How long can Forteo be used? The maximum treatment duration for Forteo is 24 months (2 years) over a lifetime. It should not be re-administered after completing the 24-month course.
Q. Is Forteo available in India? Forteo can be supplied to hospitals, orthopaedic centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the price of Forteo in India? Forteo price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Forteo from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Forteo in bulk? Yes. A.K. Pharma supplies Forteo in bulk to hospitals, orthopaedic centres, endocrinology clinics, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Why Order Forteo from A.K. Pharma?
Contact A.K. Pharma for Forteo Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
